Xarelto Still Climbs As Bayer Touts Successor
Strong Q4 For Pharma Division
Executive Summary
Bayer's pharmaceuticals chief Stefan Oelrich says that sales of treatments in the areas of ophthalmology, women’s healthcare and radiology have risen sharply, recovering from the effects of the COVID-19 pandemic.
You may also be interested in...
Shilpa Medicare’s Plan For Eylea Biosimilar Spells Ambition, But Path Not Easy
Shilpa Medicare’s plan for trials of an Eylea biosimilar shows the company’s ambition to leapfrog to a biosimilars-led growth strategy, one that Indian majors like Cipla and Lupin pivoted to post a successful generics program. However, the path isn’t going to be easy and Biocon/Viatris, Samsung Biologics are ahead
Bayer’s Koenen: Decentralized Trials For Pivotal Studies Not 'Black Or White Scenario'
A cross-section of biopharma experts, including senior executives from Bayer, Boehringer Ingelheim and Accenture, and US FDA Director at the India Office deliberate digitization and evolving trends in clinical research, including the potential of decentralized trials and metadata-driven automation.
Bayer’s Koenen: Decentralized Trials For Pivotal Studies Not 'Black Or White Scenario'
A cross-section of biopharma experts including senior executives of Bayer, Boehringer Ingelheim and Accenture and US FDA Director at the India Office deliberate digitization and evolving trends in clinical research, including the potential of decentralized trials and metadata-driven automation.